ArticleRisk management and healthcare policy2020
A Country Pandemic Risk Exposure Measurement Model.
Article in Risk management and healthcare policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- COVID-19 Pandemic Risk Assessment: Systematic Review.Risk management and healthcare policy · 2024Review
- COVID-19 cluster identification and support vector machine classifier model construction using global healthcare and socio-economic features.Epidemiology and infection · 2023Article
- Impact of good governance, economic growth and universal health coverage on COVID-19 infection and case fatality rates in Africa.Health research policy and systems · 2022Article
- Health Security, Quality of Life and Democracy during the COVID-19 Pandemic: Comparative Approach in the EU-27 Countries.International journal of environmental research and public health · 2022Article
- Public Interest, Risk, Trust, and Personal Protective Equipment Purchase and Usage: Face Masks Amid the COVID-19 Pandemic.International journal of environmental research and public health · 2022Article
- Future health spending forecast in leading emerging BRICS markets in 2030: health policy implications.Health research policy and systems · 2022Article
- Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.British journal of clinical pharmacology · 2021Article
- Appraisal of a Contact Tracing Training Program for COVID-19 in Greece Focusing on Vulnerable Populations.International journal of environmental research and public health · 2021Article
- Aerial Bots in the Supply Chain: A New Ally to Combat COVID-19.Technology in society · 2021Article
- Understanding small Chinese cities as COVID-19 hotspots with an urban epidemic hazard index.Scientific reports · 2021Article
- Analysis and Forecasting Incidence, Intensive Care Unit Admissions, and Projected Mortality Attributable to COVID-19 in Portugal, the UK, Germany, Italy, and France: Predictions for 4 Weeks Ahead.Bioengineering (Basel, Switzerland) · 2021Article
- Mapping the burden of diabetes in five small countries in Europe and setting the agenda for health policy and strategic action.Health research policy and systems · 2021Article
- A Proactive Approach to Identify the Exposure Risk to COVID-19: Validation of the Pandemic Risk Exposure Measurement (PREM) Model Using Real-World Data.Risk management and healthcare policy · 2021Article
- COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform.BioMed research international · 2021Review
- Corona-Triggered Global Macroeconomic Crisis of the Early 2020s.International journal of environmental research and public health · 2020Article
- Associating the Change in New COVID-19 Cases to GDP per Capita in 38 European Countries in the First Wave of the Pandemic.Frontiers in public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study is to develop a Pandemic Risk Exposure Measurement (PREM) model to determine the factors that affect a country's prospective vulnerability to a pandemic risk exposure also considering the current COVID-19 pandemic.
methodsTo develop the model, drew up an inventory of possible factor variables that might expose a country's vulnerability to a pandemic such as COVID-19. This model was based on the analysis of existing literature and consultations with some experts and associations. To support the inventory of selected possible factor variables, we have conducted a survey with participants sampled from people working in a risk management environment carrying out a risk management function. The data were subjected to statistical analysis, specifically exploratory factor analysis and Cronbach Alpha to determine and group these factor variables and determine their reliability, respectively. This enabled the development of the PREM model. To eliminate possible bias, hierarchical regression analysis was carried out to examine the effect of the "Level of Experienced Hazard of the Participant (LEH)" considering also the "Level of Expertise and Knowledge about Risk and Risk Management (LEK)".
resultsExploratory factor analysis loaded best on four factors from 19 variables: Demographic Features, Country's Activity Features, Economic Exposure and Societal Vulnerability (i.e. the PREM Model). This model explains 65.5% of the variance in the level of experienced hazard (LEH). Additionally, we determined that LEK explains only about 2% of the variance in LEH.
conclusionThe developed PREM model shows that monitoring of Demographic Features, Country's Activity Features, Economic Exposure and Societal Vulnerability can help a country to identify the possible impact of pandemic risk exposure and develop policies, strategies, regulations, etc., to help a country strengthen its capacity to meet the economic, social and in turn healthcare demands due to pandemic hazards such as COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.